• R Schmidt and W Oestreich.
• Medical Department, Janssen GmbH, Neuss, Germany.
• J. Cardiovasc. Pharmacol. 1991 Jan 1; 18 Suppl 8: S21-6.

AbstractApart from the treatment of migraine attacks, prophylaxis may be required when certain criteria of frequency, duration, or severity are met. In a series of placebo-controlled, double-blind studies, the effectiveness of the cerebral calcium antagonist flunarizine (Sibelium) in migraine prophylaxis was shown. In further investigations, the effectiveness of flunarizine was similar to that of propranolol, metoprolol, pizotifene, and methysergide. The side effects described for treatment with flunarizine were somnolence, weight gain, and, in rare cases, depressive mood and extrapyramidal motor disorders. Considering the benefit/risk relation, flunarizine and the beta-adrenergic agents propranolol and metoprolol are now regarded as the drugs of choice. The mechanism of action of flunarizine in migraine prophylaxis is largely unexplained, but the antihypoxic effect of flunarizine is discussed in this context. The search for predicting factors for a successful treatment with flunarizine and the investigation of an injectable solution for the treatment of acute migraine attacks must be left to future research.

8 keywords...

hide…